Core Viewpoint - The company Shijiazhuang Fourth Pharmaceutical Group has received approval from the National Medical Products Administration to produce three new pharmaceutical products, marking significant advancements in its product offerings [1] Group 1: Product Approvals - The approved products include Urapidil sustained-release capsules (30mg), Nicardipine hydrochloride sodium chloride injection (200ml), and Clonidine hydrochloride injection (2ml) [1] - Urapidil sustained-release capsules and Nicardipine hydrochloride sodium chloride injection are the first of their kind to be approved in China, indicating a competitive edge in the market [1] - Clonidine hydrochloride injection is also considered to have passed the consistency evaluation, categorized as a Class 4 chemical drug [1]
石四药集团旗下三个产品获药品生产注册批件